SamuelCharlesBlackmanMDPhD
Pediatric Hematology & Oncology • Brisbane, CAPediatric Neuro-Oncology
Founder and Chief Medical Officer, Day One Biopharmaceuticals, Inc.
Dr. Blackman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Sierra Point Pkwy
Suite 501
Brisbane, CA 94005Phone+1 650-484-0899
Summary
- Dr. Samuel Blackman is a pediatric hematologist/oncologist in Brisbane, CA. He received his medical degree from University of Illinois College of Medicine at Chicago and has been in practice 16 years. He specializes in pediatric neuro-oncology and is experienced in neuro-oncology, pediatric neuro-oncology, medical ethics, pharmacology, and drug development. He has more than 20 publications and over 500 citings.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2008- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2007
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 2001 - 2004- Cincinnati Children's Hospital Medical CenterInternship, Pediatrics, 2001 - 2002
University of Illinois College of MedicineClass of 2001
Certifications & Licensure
PA State Medical License 2008 - 2024
Clinical Trials
- Long-Term Follow-up Study for Patients Previously Treated With JCAR015 Start of enrollment: 2016 Aug 30
- A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors Start of enrollment: 2021 Apr 22
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Start of enrollment: 2023 Feb 27
- Join now to see all
Publications & Presentations
PubMed
- 33 citationsThe type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt
Nature Medicine. 2024-01-01 - 2 citationsActivity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a NovelGene Fusion.Katharine Offer, Michael T McGuire, Kunchang Song, Michael J Goldfischer, Monika A Davare
JCO Precision Oncology. 2023-07-01 - 19 citationsPaediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with p...Andrew D.J. Pearson, Kimberly Stegmaier, Franck Bourdeaut, Gregory H. Reaman, Delphine Heenen
European Journal of Cancer. 2020-11-01
Authored Content
- LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alterationJanuary 2024
Press Mentions
- Day One Biopharmaceuticals: Recent Strong Data, and Major Catalysts AheadSeptember 4th, 2022
- Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade GliomaJune 12th, 2022
- Moonshot4kids Congressional/OSTP Briefing and Reception Support DIPG Awareness Resolution for Childhood Brain CancerMay 27th, 2022
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
